甲氧氯普胺和马来酸氯苯那敏联合预防荧光素钠的不良反应

目的:评价甲氧氯普胺和马来酸氯苯那敏联合预防眼底荧光造影检查造影剂引起的不良反应。方法:将2009年12月至2011年12月收治的672例在北京市隆福医院进行眼底荧光造影检查的患者随机分成甲氧氯普胺片和马来酸氯苯那敏片联合应用组(1组)和常规组(2组)。荧光造影检查造影剂荧光素钠引起的不良反应可以分为轻、中、重和死亡四个等级。结果:患者进行3d随访,672观察病例中,发生轻度不良反应56例(8.33%);中度不良反应12例(1.79%);重度不良反应9例(1.34%);死亡0例。未发生不良反应595例(88.54%)。其中,1组轻度不良反应发生率2.32%,中度不良反应发生率0.27%,重度不良反应发生率0.82%。2组轻度不良反应发生率14.68%,中度不良反应发生率3.36%,重度发生率1.97%。1组与2组轻度不良反应发生率有显著性差异(P<0.05);1组与2组中度不良反应发生率有非常显著性差异(P<0.01);1组与2组重度不良反应发生率无统计学意义(P>0.05)。结论:联合应用甲氧氯普片和马来酸氯苯那敏片在眼底荧光造影检查中能有效地预防造影剂荧光素钠注射液引起的轻中度不良反应,对重度不良反应效果并不理想。

Metoclopramide combined with chlorpheniramine maleate in prevention of adverse reactions to sodium fluorescein

Objective： To evaluate the safety and effectiveness of metoclopramide combined with chlorpheniramine maleate for the prevention of adverse reactions to sodium fluorescein of fundus fluorescein angiography（FFA）.Methods： A total of 672 patients undertaken FFA were randomly assigned to metoclopramide combined with chlorpheniramine maleate（n=368, group 1）, or no drugs （n=304, group2）. Adverse drug reaction to sodium fluorescein have been classified as mild, moderate, severe and death. Results： Mild reaction occurred in 56 patients, moderate reaction occurred in 12 patients, severe reaction occurred in 9 patients and death 0 patients. no adverse reactions in 595 patients; incidents of severe adverse events was 1.79%（group1 0.27%,group 2 3.36%）; mild reaction 8.33% （group1 2.32%,group2 14.68% ）, there were significant difference between the two groups （P0.05）. Conclusions： It’s effective for metoclopramide and chlorpheniramine maleate for the prevention of adverse reactions to sodium fluorescein ： such as allergy, gastrointestinal symptoms in FFA.